The results showed that the survival rate of CRC patients with high expression of CEACAM7, CNTN3, CXCL3, CXCL8, SLC1A1, and SLC16A9 (p < 0.05) was higher than that in CRC patients that weakly expressed these genes (Figures 6(a)–6(e) and 6(g)). This evidence concerns the gene SLC16A9 and colorectal carcinoma.